CATALYST ONCOLOGY
LIVE

Serial Number

90606261

Owner

Catalyst Clinical Research LLC

Attorney

Philip J. Cardinale

First Use Date

Nov 25, 2020

Filing Date

Mar 26, 2021

Add to watchlist:

No watchlists yet
View on USPTO

CATALYST ONCOLOGY Trademark

Serial Number: 90606261

CATALYST ONCOLOGY is a trademark filed by Catalyst Clinical Research LLC on March 26, 2021. The trademark is classified under Class 42 (Computer & Scientific), Class 35 (Advertising & Business). The application is currently pending registration.

Owner Contact Info

Catalyst Clinical Research LLC (7 trademarks)

Wilmington, NC 28409

Entity Type: 16

Trademark Details

Filing Date

March 26, 2021

Registration Date

Not Registered

First Use Anywhere

November 25, 2020

First Use in Commerce

November 25, 2020

Goods & Services

Business consulting and information services in the field of commercializing of pharmaceuticals, medical devices, and biotechnology; project management services for others for business purposes in the field of research and development of pharmaceuticals, medical devices and biotechnology; regulatory submission management, namely, assisting others in preparing and filing applications with the governmental regulatory bodies for approval of new drugs and medical devices; economic forecasting and analysis; market research; medical consulting, namely, consulting services in the field of medical product approval for commercial purposes, providing consulting services in the field of regulatory submission management to medical companies to assist them with applications for medical device approval; clinical trial consulting, monitoring, and oversight, namely, business consulting in the field of clinical trials, namely, management and compilation of computerized databases in the field of clinical trials for business purposes, business consulting and management in the field of clinical trials, namely, management and compilation of computerized databases in the field of clinical trials for business purposes; biostatistical consulting, namely, statistical analysis and reporting services for business purposes; database management in the pharmaceutical fields; providing independent review of clinical trials for business purposes; recruitment and placing patients for participations in clinical trials

Clinical trial consulting, namely, consulting services for others in the field of design, planning, and implementation project management of clinical trials, providing medical and scientific research information in the field of pharmaceuticals and clinical trials

Filing History

REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
May 8, 2026 RCSC
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Nov 4, 2025 RCSC
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Apr 30, 2025 RCSC
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Oct 28, 2024 RCSC
TEAS CHANGE OF CORRESPONDENCE RECEIVED
May 28, 2024 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
May 28, 2024 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
May 28, 2024 REAP
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Apr 26, 2024 RCSC
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Oct 25, 2023 RCSC
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Jun 20, 2023 EWAF
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Jun 20, 2023 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jun 20, 2023 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jun 20, 2023 REAP
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Apr 25, 2023 RCSC
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Oct 20, 2022 GNS3
LETTER OF SUSPENSION E-MAILED
Oct 20, 2022 GNSL
SUSPENSION LETTER WRITTEN
Oct 20, 2022 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Aug 23, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Aug 23, 2022 CRFA
ASSIGNED TO LIE
Aug 22, 2022 ALIE
NOTICE OF REVIVAL - E-MAILED
Jul 28, 2022 NREV
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jul 27, 2022 TROA
PETITION TO REVIVE-GRANTED
Jul 27, 2022 PETG
TEAS PETITION TO REVIVE RECEIVED
Jul 27, 2022 PROA
ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
May 27, 2022 MAB2
ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
May 27, 2022 ABN2
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Nov 5, 2021 GNRN
NON-FINAL ACTION E-MAILED
Nov 5, 2021 GNRT
NON-FINAL ACTION WRITTEN
Nov 5, 2021 CNRT
ASSIGNED TO EXAMINER
Nov 3, 2021 DOCK
NOTICE OF DESIGN SEARCH CODE E-MAILED
Jul 3, 2021 MDSC
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jul 2, 2021 NWOS
NEW APPLICATION ENTERED
Mar 30, 2021 NWAP